Praxis Precision Medicines, Inc.PRAXNASDAQ

|||

Switch Symbol:

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Latest News

businesswire.com

SEQSTER Announces Expanded Partnership with Praxis Precision Medicines to Accelerate Clinical Trials in CNS Disorders

SAN DIEGO & BOSTON--(BUSINESS WIRE)--SEQSTER, the leading healthcare technology company and the data connection, collection, and orchestration layer for patient health data, and Praxis Precision Medicines, Inc., today announced the expansion of a successful partnership to accelerate clinical trials, data collection, and real-world evidence (RWE) generation across Praxis's clinical development programs. Building on early success in Praxis's innovative Essential3 Program for Essential Tremor, SEQ.

defenseworld.net

Head-To-Head Contrast: Praxis Precision Medicines (NASDAQ:PRAX) versus Atrinsic (NASDAQ:PTIX)

Atrinsic (NASDAQ: PTIX - Get Free Report) and Praxis Precision Medicines (NASDAQ: PRAX - Get Free Report) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends. Analyst Ratings This is a summary of recent

globenewswire.com

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on January 2, 2026, the Compensation Committee of Praxis' Board of Directors granted restricted stock unit awards covering an aggregate of 434 shares of its common stock to three new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees' entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).

globenewswire.com

Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments

BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation–inhibition imbalance, today announced the appointment of Jeffrey B. Kindler and Stuart Arbuckle to its board of directors, and the promotions of Megan Sniecinski to Chief Operating Officer and Dr. Steven Petrou to President of Research & Development.

globenewswire.com

Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering

BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced the pricing of its underwritten public offering of 2,212,000 shares of its common stock at a public offering price per share of $260.00. The gross proceeds from the offering are expected to be approximately $575 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Praxis. All shares in the offering are being offered by Praxis. In addition, Praxis has granted the underwriters a 30-day option to purchase up to 331,800 additional shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about January 8, 2026, subject to market conditions and the satisfaction of customary closing conditions.

globenewswire.com

Praxis Precision Medicines, Inc. Announces Proposed Public Offering

BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced a proposed public offering of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of common stock. All securities in the offering will be offered by Praxis. In addition, Praxis intends to grant the underwriters a 30-day option to purchase additional shares of common stock in an amount up to 15% of the shares of common stock (or pre-funded warrants in lieu thereof) sold in the offering at the public offering price, less the underwriting discount and commission.

fool.com

Why Praxis Precision Medicines Stock Popped Today

Millions of people suffer from movement disorders. Praxis Precision Medicines wants to help meet the large unmet need for effective treatment options.

gurufocus.com

Praxis Precision Medicines Soars on FDA Breakthrough Therapy Designation

Praxis Precision Medicines (PRAX) is experiencing a significant surge, reaching multi-year highs following the announcement that the FDA has granted Breakthroug

benzinga.com

Praxis Precision Medicines To Rally More Than 213%? Here Are 8 Top Analyst Forecasts For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

schaeffersresearch.com

Stock Futures Slip as Investors Take Profit on Tech Stocks

Stock futures are lower as tech stocks and commodities succumb to profit taking

globenewswire.com

Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor

The Breakthrough Therapy Designation was granted based on the positive topline results from the Essential3 Phase 3 program in essential tremor

247wallst.com

Here Are Monday’s Top Wall Street Analyst Research Calls: Doximity, KB Home, NVIDIA, Okta, On Holdings, Take-Two Interactive, Vail Resorts, and More

Pre-Market Stock Futures: The futures are trading lower as we begin the final trading week of 2025, albeit a holiday-shortened one once again. The major indices all finished the session modestly lower on Friday, with the venerable S&P 500 taking early bows as it hit a fresh all-time high, joining the Dow Jones Industrial Average... Here Are Monday's Top Wall Street Analyst Research Calls: Doximity, KB Home, NVIDIA, Okta, On Holdings, Take-Two Interactive, Vail Resorts, and More.

defenseworld.net

Assenagon Asset Management S.A. Has $21.72 Million Stock Position in Praxis Precision Medicines, Inc. $PRAX

Assenagon Asset Management S.A. cut its position in Praxis Precision Medicines, Inc. (NASDAQ: PRAX) by 32.2% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 409,779 shares of the company's stock after selling 194,519 shares during the quarter. Assenagon Asset

globenewswire.com

Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026

EMBOLD data to serve as basis of efficacy and safety following discussion with the FDA EMBOLD data to serve as basis of efficacy and safety following discussion with the FDA

globenewswire.com

Praxis Precision Medicines Announces Alignment with FDA on Simplified and Accelerated Registrational Pathway for Elsunersen in Early Onset SCN2A Developmental and Epileptic Encephalopathy

Clear recognition of high unmet need and urgency for the SCN2A community and plausibility of the mechanism of elsunersen

zacks.com

PRAX Stock Skyrockets 520% in 3 Months: Here's What You Need to Know

Praxis stock soars after late-stage data show strong efficacy for ulixacaltamide therapy in essential tremor and momentum builds toward an early-2026 regulatory filing.

defenseworld.net

Praxis Precision Medicines (NASDAQ:PRAX) Reaches New 52-Week High – Here’s Why

Praxis Precision Medicines, Inc. (NASDAQ: PRAX - Get Free Report)'s share price reached a new 52-week high on Friday. The stock traded as high as $249.97 and last traded at $255.4490, with a volume of 59852 shares changing hands. The stock had previously closed at $189.97. Analyst Ratings Changes A number of research analysts have

benzinga.com

Praxis' Epilepsy Drug Too Good To Continue, FDA Meeting Up Next

Praxis Precision Medicines Inc. (NASDAQ: PRAX) stock rose Friday after the company shared results from the registrational cohort of the EMBOLD study evaluating relutrigine for the treatment of patients with SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs).

feeds.benzinga.com

Praxis Precision Medicines Stock Surges 25% In Friday Pre-Market Trading— What's Going On?

Praxis Precision Medicines Inc. (NASDAQ: PRAX) shares surged 24.81% in pre-market trading on Friday, climbing to $237.10- what's going on?

globenewswire.com

Praxis Precision Medicines Announces Positive Results from EMBOLD Study for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies

Successful interim analysis triggered early stop for efficacy Topline study results to be shared at the American Epilepsy Society Annual Meeting on December 6, 2025 Praxis confirms an upcoming meeting with the FDA to discuss the results and NDA path BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced positive results from the registrational cohort of the EMBOLD study evaluating relutrigine for the treatment of patients with SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs), following a recommendation by the Data Monitoring Committee to stop the study early for efficacy. “SCN2A and SCN8A DEEs are devastating conditions with extremely high mortality due to the debilitating seizure burden they impose on patients, and there are currently no approved treatment options.

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance